IHC - GCDFP15- Test, Price, Normal Range | Sprint Diagnostics Hyderabad

No, fasting is not required for this test.

The sample is usually collected by a healthcare professional during a biopsy procedure where a small piece of tissue is removed for examination.

A positive result suggests the presence of cells expressing GCDFP15, which is usually associated with cells originating from breast tissue. However, it's important to discuss the results with your healthcare provider for a complete interpretation.

The frequency of this test depends on the clinical context and is determined by your healthcare provider.

No specific precautions are required for this test.

Certain factors may influence the test results, including the type and stage of the cancer.

If the test value is abnormal, you should consult an oncologist or a pathologist for further advice and management.

The pain associated with this test is mostly from the biopsy procedure used to collect the tissue sample.

While the test can help identify the presence of certain cancer cells, it does not determine the stage of the cancer. Further tests would be needed for staging.

This test can aid in determining the origin of metastatic cancer when the primary source is unknown.

A negative result does not necessarily exclude breast origin as not all breast cancers express GCDFP15. Always discuss your results with your healthcare provider.

There are no known modifiable factors that can affect GCDFP15 levels as it is related to the presence of certain cancer cells.

Yes, the type and stage of the cancer are non-modifiable factors that can affect the levels of GCDFP15.

There's no specific preparation required for this test. However, you should follow your healthcare provider's instructions regarding the biopsy procedure.

As the sample for this test is usually collected through a biopsy, potential risks are those associated with a biopsy procedure. These might include infection, bleeding, or an allergic reaction to anesthesia. However, these risks are generally low as the procedure is performed under sterile conditions.

A positive result indicates the presence of GCDFP15, generally associated with cells originating from breast tissue. This doesn't establish a definitive diagnosis, but it provides valuable information to your healthcare provider. If you get a positive result, you should discuss with your healthcare provider about the next steps, which might include further testing, imaging, or treatment planning.

A negative result does not necessarily rule out breast cancer as not all breast cancers express GCDFP15. If your result is negative, your healthcare provider will guide you through what the next steps might be, based on your overall clinical picture.

Yes, the IHC-GCDFP15 test can be useful in monitoring the treatment progress in some cases, especially if the initial test was positive. Repeat testing can help determine if the treatment is working by ing a decrease in GCDFP15 expression.

Yes, usually the GCDFP15 IHC test is one part of a comprehensive diagnostic process that may include other tests such as imaging studies, molecular tests, other IHC tests, and sometimes even genetic tests.

Medications do not directly affect the result of the IHC-GCDFP15 test. However, medications that affect the growth and spread of cancer cells could indirectly affect the test results. Always inform your healthcare provider about any medications you are currently taking.

This test is particularly useful for those diagnosed with cancer of unknown primary origin. It's also used when breast cancer is suspected based on other diagnostic tests or clinical examination. However, its suitability and necessity are determined by your healthcare provider based on your specific clinical situation.